With bucks from Pfizer added to their new round, Amplyx steers a tricky course through PhII and a global pandemic

After beefing up its pipeline last year with an in-licensing deal from Novartis, San Diego-based Amplyx has lined up an extension of their C round, designed to pay their way through a slate of mid-stage trials putting their experimental drugs to the test in humans. And this time they’re getting some bucks from Pfizer to pay for the next leg in the development process.